MaxCyte secures $75M credit facility to fund Akron Bio acquisition
What's the deal? MaxCyte has secured a credit facility of up to $75 million from MidCap FinancialDealroom has a profile for this one. Try Dealroom →, comprising a $55 million term loan and a $20 million revolving facility. The Rockville, Maryland-based cell-engineering company plans to draw just $22 million at closing — $20 million from the term loan and $2 million from the revolver.
Why now? The financing is tied to MaxCyte's agreement, announced November 10, to acquire Akron BioProducts for $151.8 million in cash, stock, and deferred payments. The company will pay $105 million in cash at closing, issue shares valued at roughly $26.8 million, and make two $10 million deferred payments due in January 2028 and January 2029.
What's the endgame? Akron, based in Boca Raton, Florida, supplies GMP-grade reagents and materials used in cell and gene therapy manufacturing. The deal extends MaxCyte beyond its core non-viral electroporation technology and is expected to nearly double its revenue base.
Akron is projected to generate about $28 million in revenue and $7 million to $8 million in EBITDA in 2026, with positive cash flow. MaxCyte expects that to cut the combined company's annual cash burn to less than $10 million in 2027.
What could go wrong? Liquidity is tight. MaxCyte reported $132.7 million in cash and investments at September 30, but the acquisition is expected to leave it with roughly $40–45 million by year-end. The company says the initial drawdowns, plus cash on hand and remaining facility availability, should fund operations through profitability.
"This acquisition represents a significant step forward for us," said Maher Masoud, MaxCyte's president and chief executive officer, adding it would "accelerate our path to profitability."
The signal: The credit facility is better read as acquisition and runway financing than a growth round. It arrives amid a tough climate for cell-therapy developers — Caribou Biosciences recently halted programs and sought strategic alternatives after struggling to raise capital — making MaxCyte's bet on recurring consumables revenue a test of whether consolidation can buy a path to profit.
Read more: ca.marketscreener.com
Image credit: Generated with Gemini
